



Lin-Zhi International, Inc.

REF 0117		Description	Quantity
0117	CONTROL -	LZI Methadone Level 1 Control (225 ng/mL)	1 x 5 mL
0118	CONTROL +	LZI Methadone Level 2 Control (375 ng/mL)	1 x 5 mL

Intended Use

The LZI Methadone Controls are for use as assayed quality control materials to monitor the precision of the LZI Methadone and Methadone II Enzyme Immunoassay (Ref# 0110/0111 and Ref# 0630/0631) on a number of automated clinical chemistry analyzers. (1, 2)

Description of the Controls

The LZI Methadone Controls are human urine-based liquid and ready-to-use. The constituent is a processed drug-free human urine matrix containing buffers, stabilizers, and less than 0.1 % of sodium azide. The controls are prepared by spiking known concentrations of methadone into the drug-free matrix.

*Actual concentrations of these controls are confirmed by GC/MS or LC/MS. Values are provided only as guidelines and laboratories should determine the ranges based on their own test system and tolerance. (3)

Precautions and Warning

- The LZI Methadone Controls are for in vitro diagnostic use only. Harmful if swallowed.
- The controls contain sodium azide, which may react with lead or copper plumbing to form potentially explosive metal azide. When disposing such liquids always flush with a large volume of water to prevent azide build-up. (4)
- The controls are prepared from non-sterile human urine. They are not tested by licensed reagents for the presence of antibodies to human immunodeficiency viruses, the hepatitis antigens, and/or anti- hepatitis antibodies. They should be handled as potentially infectious. Always apply good laboratory practice to avoid any skin contact or ingestion.
- Do not use the controls beyond their expiration dates.
- Refer USA: Cautions: Federal law restricts this device to sale by or on the order of a physician.

Preparation and Storage

The controls are provided ready-to-use. No reconstitution is required. Label the cap before removal to identify it with the original bottle. The controls should be stored refrigerated at 2-8°C when not in use.

Stability

When stored refrigerated at 2-8°C, the controls are stable either opened-recapped or unopened until the expiration date printed on the vial label. Store controls tightly capped when not in use. Controls solution dispensed in the sample cups and left on board of the clinical analyzer should be discarded after use.

Procedure and Results

Both levels of controls 225 ng/mL and 375 ng/mL should be run daily to ensure proper assay performance. Additionally, run the controls with each new calibration and after specific maintenance or troubleshooting procedures are performed. For interpretation of results, refer to the appropriate LZI Methadone or LZI Methadone II Enzyme Immunoassay (Ref# 0110/0111 or Ref# 0630/0631) package inserts. (1, 2)

Limitations

The LZI Methadone Controls are for use with the LZI Methadone or LZI Methadone II Enzyme Immunoassay (Ref# 0110/0111 or Ref# 0630/0631) to detect methadone in human urine only. (1, 2) Quality control materials should be used in accordance with local, state, and/or federal regulations or accreditation requirements.

Symbols Used								
EC REP	Authorized Representative	IVD	In Vitro Diagnostic medical device	SDS	Safety Data Sheet			
<u>&</u>	Biological Risks	LOT	Lot Number	2°C	Temperature Limits			
()	CE Mark	444	Manufacturer	T.K.	Test Kit Number			
Ĩ	Consult Instructions for Use		Negative Control	Σ	Use-by Date			
CONTENTS	Contents	CONTROL +	Positive Control					
GTIN	Global Trade Item Number	REF	Reference Number					
1								

Bibliography

- 1. LZI Methadone Enzyme Immunoassay (Ref# 0110/0111) package insert.
- 2. LZI Methadone II Enzyme Immunoassay (Ref# 0630/0631) package insert.
- 3. Guidance for Industry and FDA Staff, Assayed and Unassayed Quality Control Material. U.S. Department of Health and Human Services. FDA, Document issued on June 7, 2007.
- 4. Sodium Azide. National Institute for Occupational Safety (NIOSH). Pocket Guide to Chemical Hazards. Third Printing, September 2007. Available online at: https://www.cdc.gov/niosh/npg/default.html

Additions, deletions, or changes are indicated by a change bar in the margin.

Notice: Adulteration of reagents, use of instruments without appropriate capabilities, or other failure to follow instructions as set forth in this labeling can affect performance characteristics, and stated or implied label claims.



EC REP Authorized European Rep. within the EU: CEpartner4U

Lin-Zhi International, Inc. 2945 Oakmead Village Court Santa Clara, CA 95051 USA Tel: (408) 970-8811 Fax: (408) 970-9030 www.lin-zhi.com CEpartner4U Esdoornlaan 13 3951 DB Maarn The Netherlands www.cepartner4u.eu

© December 2020 Rev. 7

CE